BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Globe Newswire•18/09/2026•07:00 ET
0
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering
Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC
Get started
Create a free account to read the full story and Whiz Insights.